CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness. Chen R, Pang X, Li F, Wu S, Wang Y, Zheng X, Zhao Y, Qiu F, Chen L, Du F, et al. Front Immunol. 2026; 17:1886034. PMID: 42807306. Abstract CommentRecommendBookmarkWatch
